VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,700 shares, an increase of 112.5% from the December 15th total of 800 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is presently 0.2 days.
Institutional Trading of VanEck Biotech ETF
Several large investors have recently added to or reduced their stakes in the company. Truist Financial Corp grew its holdings in shares of VanEck Biotech ETF by 3.8% during the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock valued at $455,000 after buying an additional 100 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its position in VanEck Biotech ETF by 4.6% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after acquiring an additional 141 shares during the period. Truvestments Capital LLC purchased a new position in VanEck Biotech ETF during the 3rd quarter valued at about $44,000. FSA Wealth Management LLC acquired a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at about $54,000. Finally, Coastline Trust Co purchased a new position in VanEck Biotech ETF during the third quarter valued at approximately $59,000. 32.05% of the stock is owned by institutional investors and hedge funds.
VanEck Biotech ETF Stock Performance
Shares of BBH traded down $1.02 during midday trading on Thursday, hitting $158.45. The stock had a trading volume of 10,570 shares, compared to its average volume of 10,927. The business has a 50-day simple moving average of $162.70 and a two-hundred day simple moving average of $171.65. VanEck Biotech ETF has a fifty-two week low of $151.35 and a fifty-two week high of $183.64.
VanEck Biotech ETF Dividend Announcement
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Stories
- Five stocks we like better than VanEck Biotech ETF
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What is a Death Cross in Stocks?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a SEC Filing?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.